TKMR News Alert Tekmira Pharmaceuticals Corp (TKMR) 24.68 01/12/2015

New Post Public Reply Private Reply Replies (0) Message Board

Jan 12, 2015 at 5:52 PM

Tekmira Pharmaceuticals Corp (TKMR) 24.68 $TKMR

Bristol-Myers and Tiffany are big market movers
AP - 1 hr 8 mins ago
NEW YORK (AP) — Stocks that moved substantially or traded heavily Monday on the New York Stock Exchange and the Nasdaq Stock Market:
FMI: 46.74 (+22.81), SHPG: 209.10 (-8.39), BBW: 21.75 (+3.12), TKMR: 24.68 (+8.98), NPSP: 45.35 (+3.44), TIF: 89.01 (-14.44), BMY: 62.18 (+1.86), CVX: 105.88 (-2.33), TKM.TO: 29.38 (+10.55)

Tekmira Purchases OnCore Biopharma To Find Hep B Cure
at Investor's Business Daily - Mon Jan 12, 12:49PM CST
Tekmira Pharmaceuticals (TKMR) stock soared on Monday after the Canadian drugmaker said Sunday that it would buy privately held OnCore Biopharma to bolster its efforts to develop a cure for hepatitis B. The merged company has the potential to become...
TKMR: 24.68 (+8.98)

Nasdaq stocks posting largest percentage increases
AP - Mon Jan 12, 12:23PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
AGEN: 6.17 (+0.88), CLUB: 7.19 (+0.93), EVOK: 7.52 (+0.82), SCYX: 14.50 (+1.66), TKMR: 24.68 (+8.98), TKM.TO: 29.38 (+10.55)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Jan 12, 11:46AM CST

CLUB: 7.19 (+0.93), FRO: 4.63 (+0.69), NES: 3.20 (-1.09), ARWR: 6.90 (-2.16), BBW: 21.75 (+3.12), TKMR: 24.68 (+8.98), NADL: 1.25 (-0.16), TIF: 89.01 (-14.44), BITA: 74.04 (-15.07), CPXX: 2.78 (+0.37), AGEN: 6.17 (+0.88), TOPS: 1.49 (+0.24), IRMD: 15.88 (+2.48), FMI: 46.74 (+22.81), SRPT: 11.91 (-2.04), REXX: 2.94 (-0.74), LOCM: 0.74 (-0.32), BLFS: 2.10 (-0.17), SNDK: 83.57 (-13.47), AWX: 3.15 (+0.27)

Today's Market: Pharma And Biotech M&A Start 2015 With A Bang
Matthew Smith - at Seeking Alpha - Mon Jan 12, 9:13AM CST

ABC: 90.93 (-2.07), FMI: 46.74 (+22.81), MWIV: 190.00 (+14.35), GILD: 101.21 (-1.00), SHPG: 209.10 (-8.39), TKMR: 24.68 (+8.98), NPSP: 45.35 (+3.44), ABBV: 65.76 (-0.02)

Tekmira teams up with OnCore to focus on hepatitis B cure
By The Associated Press - AP - Mon Jan 12, 8:52AM CST
Shares of Tekmira Pharmaceuticals soared Monday after the Canadian drugmaker said it would buy privately held OnCore Biopharma to form a team focused on developing a hepatitis B cure.
GILD: 101.21 (-1.00), TKMR: 24.68 (+8.98), TKM.TO: 29.38 (+10.55)

Tekmira Pharmaceuticals (TKMR) Stock Soars After OnCore Biopharma Acquisition Announcement
at The Street - Mon Jan 12, 8:50AM CST
Shares of Tekmira Pharmaceuticals (TKMR) surged in morning trading Monday after the company agreed to acquire OnCore Biopharma to shift focus to developing hepatitis B virus treatments.
TKMR: 24.68 (+8.98)

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Jan 12, 8:14AM CST

EYES: 11.75 (+0.91), ZIOP: 5.93 (+0.55), OIBR: 2.16 (-0.41), ARWR: 6.90 (-2.16), TKMR: 24.68 (+8.98), SN: 8.56 (-0.32), TIF: 89.01 (-14.44), NBG: 1.66 (+0.09), BMY: 62.18 (+1.86), LULU: 62.59 (+3.96), CPXX: 2.78 (+0.37), AGEN: 6.17 (+0.88), GDP: 2.85 (-0.39), FMI: 46.74 (+22.81), ASNA: 11.44 (-0.20), NPSP: 45.35 (+3.44), AMCO: 1.90 (+0.34), SNDK: 83.57 (-13.47)

Tekmira/Oncore Merger Represents Substantial Upside
Dr. Paul Nunzio DeSantis, Pharm.D - Seeking Alpha - Mon Jan 12, 7:49AM CST
Well, one IPO we were eagerly awaiting is no longer on this year's docket with Tekmira (NASDAQ: TKMR )'s merger agreement with Oncore announced tonight all plans for any anticipated IPO this year are now null and void. However, we believe TKMR will...
GBIM: 7.49 (-0.34), ISIS: 73.34 (+1.08), ALNY: 103.78 (+2.48), ARWR: 6.90 (-2.16), SHPG: 209.10 (-8.39), TKMR: 24.68 (+8.98)

Wall Street Breakfast: Week Begins With Healthcare Deals
Wall Street Breakfast - at Seeking Alpha - Mon Jan 12, 5:31AM CST

TSLA: 202.21 (-4.45), BIIB: 347.84 (+5.50), F: 15.22 (+0.01), TKMR: 24.68 (+8.98), RBS: 11.13 (-0.01), K: 65.48 (-0.95), JNJ: 104.58 (-0.36), SPY: 202.65 (-1.60), QQQ: 101.55 (-1.07), FMI: 46.74 (+22.81), SHPG: 209.10 (-8.39), TSEM: 13.33 (-0.10), GPRE: 22.31 (-0.58), GM: 35.84 (+0.25), ABBV: 65.76 (-0.02), NDAQ: 47.35 (-1.15), BABA: 101.62 (-1.40)

Tekmira Pharmaceuticals and OnCore Biopharma Announce Merger Agreement to Create Leading Global Hepatitis B Virus Company
Thomson Reuters ONE - Sun Jan 11, 9:09PM CST
Transaction Highlights:
TKMR: 24.68 (+8.98), TKM.TO: 29.38 (+10.55)

Tekmira merges with firm developing HBV cure
Seeking Alpha - at Seeking Alpha - Sun Jan 11, 8:55PM CST

TKMR: 24.68 (+8.98)

J&J Starts Ebola Vaccine Study, Updates Production Goal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 07, 5:00PM CST
Johnson & Johnson (JNJ) commenced a phase I study on a preventive Ebola vaccine to evaluate the safety and tolerability of the Ebola vaccine regimen.
JNJ: 104.58 (-0.36), TKMR: 24.68 (+8.98), GSK: 42.93 (+0.13)

Tekmira Jumped Following Update on its Oncology Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 02, 4:20PM CST
Tekmira Pharmaceuticals' (TKMR) shares increased almost 9% after it provided updates from phase I/II studies on TKM-PLK1.
TKMR: 24.68 (+8.98), AMGN: 156.22 (+0.49), AMAG: 42.32 (-0.12)

Seeking Alpha's Biotech Weekly: 2014's Approval-Palooza, Ebola In Scotland, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Jan 02, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
ACC: 43.44 (+0.40), JNJ: 104.58 (-0.36), NVO: 43.70 (+0.49), OGXI: 2.30 (+0.01), GILD: 101.21 (-1.00), ONVO: 6.69 (-0.33), TKMR: 24.68 (+8.98), TEVA: 57.01 (+0.29), MDXG: 8.79 (-0.48)

Technical Coverage on Biotech Stocks - Arena Pharma, XOMA, Dyax, Mast Therapeutics, and Tekmira Pharma
PR Newswire - Fri Jan 02, 7:50AM CST
Investor-Edge has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), XOMA Corporation (NASDAQ: XOMA), Dyax Corporation (NASDAQ: DYAX), Mast Therapeutics Inc. (NYSE MKT: MSTX), and Tekmira Pharmaceuticals Corporation (NASDAQ: TKMR). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Wednesday, December 31, 2014, the NASDAQ Composite ended at 4,736.05, down 0.87%, the Dow Jones Industrial Average declined 0.89%, to finish the day at 17,823.07, and the S&P 500 closed at 2,058.90, down 1.03%. The losses were broad based as all the sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 791.97, down 0.98%, while the index has advanced 7.03% in the previous three months. Register for your complimentary reports on these five stocks at:
MSTX: 0.54 (+0.02), TKMR: 24.68 (+8.98), ARNA: 5.65 (+0.22), DYAX: 14.41 (+0.12), XOMA: 3.73 (+0.07)

Rewards Outweigh Risks: Research Reports on Walgreens, Tekmira, RedHill, Verso, and Pacific Ethanol
PR Newswire - Fri Jan 02, 6:40AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Walgreens (NASDAQ: WBA), Tekmira (NASDAQ: TKMR), RedHill (NASDAQ: RDHL), Verso (NYSE: VRS), and Pacific Ethanol (NASDAQ: PEIX). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
WBA: 75.70 (+0.03), RDHL: 14.91 (+0.66), VRS: 3.17 (-0.18), TKMR: 24.68 (+8.98), PEIX: 8.43 (-1.04)

Meadowbrook and NephroGenex are big market movers
AP - Wed Dec 31, 3:15PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Wednesday on the New York Stock Exchange and the Nasdaq Stock Market:
REN: 0.81 (-0.03), TKMR: 24.68 (+8.98), CVEO: 3.28 (+0.02), CVX: 105.88 (-2.33), MIG: 8.35 (-0.02), TKM.TO: 29.38 (+10.55)

Tekmira Pharmaceuticals (TKMR) Stock Surges Today After Clinical Study Update
at The Street - Wed Dec 31, 1:42PM CST
Shares of Tekmira Pharmaceuticals (TKMR) spiked Wednesday after the company provided an update on a Phase I/II clinical study.
TKMR: 24.68 (+8.98)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Worldline Crowned as 2026 SPARK Matrix Leader

Worldline's Journey to Leadership When you talk about the big dogs in payment services, Worldline’s name crops up for a reason. They've just snagged a top spot in the 2026 SPARK Matrix by the QKS Group, putting them in the limelight as a leader in Merchant Payment Platform technology. If you're in payments, this is worth a double take. The SPARK Matrix Breakdown The...

Beta Bionics Faces Class Action Over iLet Device Concerns

Securities Fraud Allegations Hit Beta Bionics Here's a fresh one on the market front—Beta Bionics is in hot water, and it's not looking pretty. The ticker NASDAQ:BBNX is swirling in the chaos of a class action lawsuit, thanks to a stock tumble that would make even seasoned traders cringe. What's got investors riled up? The nitty-gritty centers on accusations that the...

Franklin Financial Q3: 59% Net Income Surge Amid Growth

Soaring Net Income and Impressive Growth Franklin Financial Services Corporation (NASDAQ: FRAF) seems to be on a roll this year, painting a vivid picture of growth as they close out the third quarter of 2026. With a strong surge in net income—59.4% up from Q3 2025—this leadership in earnings is no fluke. Net Income and Earnings per Share Let's break it down: the...

Etisalat Surges: Net Profit Soars 46% Amid Growth

Etisalat's Stellar Performance: A Deeper Dive When a company like Etisalat drops news of a whopping 46% increase in net profit year-over-year, you sit up and pay attention. Those numbers aren’t just a flash in the pan; they're the result of some serious strategic maneuvers and ripe market conditions. Etisalat isn't resting on its laurels, and their latest financials...

Sands China Unveils $1B Senior Notes, Eyes Debt Maneuvering

A New Play in the Sands Well, here we go again with Las Vegas Sands (NYSE: LVS) putting together another financial puzzle. Sands China, their big performer over in Macao, is selling off $1 billion in senior unsecured notes. They're splitting it with $700 million at 6.400% due in 2032 and $300 million at a heftier 6.700% maturing in 2033. This feels like classic strategic...

Altitude+ and ViewLift Celebrate Record Fan Engagement

Fresh Off the Bench: Altitude+ Rises Picture this: you're cruising through October, watching the leaves fall and the puck drop, and here come Altitude+ and ViewLift boasting some record numbers. This ain't your everyday puff piece — they've got concrete results to back it up. Altitude+, charging into the 2026–27 NHL and NBA seasons, isn't just surviving; they're...

NJ's $21.3M Water Fix Fights PFAS, Boosts AWK

Water Woes Culminate in Triumph Alright, folks, you don't often see New Jersey in the headlines for anything groundbreaking in the right way, but here we are. The big news is a hefty $21.3 million project completion that finally puts some ammo against the notorious PFAS chemicals. If you've got any skin in the utility game or just a stake in clean water, this one's been...

Leadership Shake-Up at Equity LifeStyle Properties

Shifting Gears at the Top When the calendar flips to 2027, Equity LifeStyle Properties, Inc. (NYSE:ELS) will be kicking off the new year with a fresh lineup at the helm. After 13 long years steering the ship, Marguerite Nader is moving into the role of Executive Vice Chair of the Board of Directors, paving the way for Patrick Waite to step into her shoes as President and...

Kyungtz'e Eosan Sooryukje: Honoring Spirits and History

An Enchanting Ritual Comes to NYC Some things transcend the humdrum of everyday life, and right now, New York's set to witness exactly that. It's not every day you get treated to Korea's deep-rooted Buddhist traditions, but come November 13 and 14, that's precisely what's in store. The Korean Cultural Center New York (KCCNY) is bringing Kyungtz'e Eosan Sooryukje to the...

Strategic Resources Faces Board Shakeup, AGM Announced

A Shift in Strategic Resources' Boardroom Dynamics On days like these, companies aren't just ticking boxes. They're repositioning themselves for a future painted with a whole bunch of ‘what ifs’, and Strategic Resources Inc. is no exception. This isn’t just your run-of-the-mill board shuffle—Michael Moore’s resignation marks a pivot moment. Now, you might ask...